This study aims to investigate the association between serum biomarkers and clinical response to anti-VEGF or dexamethasone implant by assessing OCT-biomarkers in patients with diabetic macular edema, DME, and to compare these with a group of naive patients (those not previously treated for DME).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Serum levels of Vascular Endothelial Growth Factor (VEGF)
Timeframe: At baseline (and for group 3. naive patients also after 4 weeks)
Serum levels of interleukin 6 (IL-6)
Timeframe: At baseline (and for group 3. naive patients also after 4 weeks)
Serum levels of interleukin 8 (IL-8)
Timeframe: At baseline (and for group 3. naive patients also after 4 weeks)
Serum levels of monocyte chemoattractant protein 1 (MCP-1)
Timeframe: At baseline (and for group 3. naive patients also after 4 weeks)
Serum levels of angiopoietin 2 (Ang-2)
Timeframe: At baseline (and for group 3. naive patients also after 4 weeks)
Serum levels of placental growth factor (PlGF)
Timeframe: At baseline (and for group 3. naive patients also after 4 weeks)
Serum levels of tumor necrosis factor alpha (TNF-a)
Timeframe: At baseline (and for group 3. naive patients also after 4 weeks)
Imadeddin Abu Ishkheidem, M.D.
Serum levels of intercellular adhesion molecule 1 (ICAM-1)
Timeframe: At baseline (and for group 3. naive patients also after 4 weeks)